Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

Eli Lilly’s momentum stems from blockbuster ... LLY’s pipeline spans promising Alzheimer’s drug donanemab, precision oncology, and AI-led antimicrobials, with OpenAI-backed supercomputing ...

Feb 5 (Reuters) - Eli Lilly (LLY.N), opens new tab investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales of popular weight-loss drug ...

Today, we have a look at the White House's reported plans to make major cuts across federal health agencies. Also, Eli Lilly ...

The integration of AI in healthcare as a means by which to enhance diagnostic accuracy and treatment planning also appeared ...

INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced ...

While we acknowledge the potential of Eli Lilly and Company (NYSE:LLY) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns ...

Axcelis Technologies, Inc. , a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced today that it will showcase its innovative Puriontm platform of ion ...

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture capital firm , discusses how AI’s uptake in healthcare will shape its ...

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA ... progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.